These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 29605876)

  • 21. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
    Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H; Kosaka T; Oya M
    Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939.
    Pudova E; Kobelyatskaya A; Katunina I; Snezhkina A; Nyushko K; Fedorova M; Pavlov V; Bulavkina E; Dalina A; Tkachev S; Alekseev B; Krasnov G; Volodin V; Kudryavtseva A
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells.
    Cristofani R; Montagnani Marelli M; Cicardi ME; Fontana F; Marzagalli M; Limonta P; Poletti A; Moretti RM
    Cell Death Dis; 2018 Aug; 9(9):889. PubMed ID: 30166521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
    Keresztes D; Csizmarik A; Nagy N; Módos O; Fazekas T; Bracht T; Sitek B; Witzke K; Puhr M; Sevcenco S; Kramer G; Shariat S; Küronya Z; Takács L; Tornyi I; Lázár J; Hadaschik B; Lászik A; Szűcs M; Nyirády P; Szarvas T
    J Cell Mol Med; 2022 Feb; 26(4):1332-1337. PubMed ID: 34970839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer.
    Ma X; Zou L; Li X; Chen Z; Lin Z; Wu X
    Cancer Biother Radiopharm; 2019 Apr; 34(3):181-188. PubMed ID: 30855185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
    Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ
    Mol Cancer Ther; 2014 Jan; 13(1):190-201. PubMed ID: 24194567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel radiosensitizes castration-resistant prostate cancer by downregulating CAV-1.
    Tu KJ; Roy SK; Keepers Z; Gartia MR; Shukla HD; Biswal NC
    Int J Radiat Biol; 2024; 100(2):256-267. PubMed ID: 37747697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
    Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
    Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
    Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
    Magadoux L; Isambert N; Plenchette S; Jeannin JF; Laurens V
    Int J Oncol; 2014 Sep; 45(3):919-28. PubMed ID: 24969394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
    Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
    Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
    Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.